Pharmaceutical Analytical Chemistry: Open Access
Open Access

Integrating Multivariate Analysis for Comprehensive Quality Assurance in Pharmaceutical Impurity Profiling

Ravi Shah^{* *}Correspondence: Ravi Shah, Department of Analytical Chemistry, University of Satavahana, Telangana, India, Email:

Author info »

Description

In the field of pharmaceuticals, ensuring product safety and efficacy is most important. Impurity profiling, the process of identifying and quantifying impurities in pharmaceutical products, stands as a basis of quality assurance protocols. This article delves into the significance of impurity profiling, its methodologies, regulatory aspects, and its pivotal role in safeguarding public health.

Understanding impurities

Impurities in pharmaceuticals can originate from various sources including raw materials, synthesis by-products, degradation of Active Pharmaceutical Ingredients (APIs), or even interactions during formulation or storage [1]. These impurities can possess diverse chemical properties and may range from organic compounds to inorganic materials, posing potential risks to patient health [2].

Importance of profiling

Impurity profiling serves multiple purposes in pharmaceutical manufacturing. Firstly, it aids in ensuring compliance with regulatory standards such as the International Council for Harmonisation (ICH) guidelines, which mandate the identification and quantification of impurities. Secondly, it enables manufacturers to assess the purity of their products, thereby enhancing safety and efficacy [3]. Moreover, impurity profiling facilitates the identification of potential degradation pathways, guiding formulation improvements and storage conditions.

Methodologies

Several analytical techniques are employed in impurity profiling, each offering unique advantages. High-Performance Liquid Chromatography (HPLC) remains a basis, allowing for the separation and quantification of impurities with high sensitivity [4]. Gas Chromatography (GC) is recommend for volatile impurities, while Mass Spectrometry (MS) aids in structural elucidation. Other techniques such as Nuclear Magnetic Resonance (NMR) spectroscopy and Infrared (IR) spectroscopy complement chromatographic methods, offering insights into impurity structure and chemical composition [5].

Challenges and solutions

Despite advancements in analytical techniques, impurity profiling poses challenges. One such challenge is the detection and quantification of trace-level impurities, which demands highly sensitive analytical methods. Additionally, the complexity of pharmaceutical matrices and the presence of closely related impurities can obstruct accurate quantification [6]. To address these challenges, continuous method development and validation are essential, alongside the implementation of strong quality control measures.

Regulatory perspective

Regulatory agencies worldwide enforce stringent guidelines pertaining to impurity profiling [7]. The ICH guidelines, particularly Q3A (Impurities in new drug substances) and Q3B (Impurities in new drug products), outline requirements for the identification, qualification, and control of impurities in pharmaceuticals [8]. These guidelines establish acceptable limits for specified and unspecified impurities, ensuring product safety and quality consistency across different markets.

Industry perspectives

In the pharmaceutical industry, impurity profiling is integral to the drug development process. From early-stage research to commercial production, rigorous impurity characterization is conducted to mitigate risks and meet regulatory requirements [9]. Moreover, advancements in analytical technology continue to streamline impurity profiling workflows, enhancing efficiency and accuracy.

Future directions

As pharmaceutical manufacturing evolves, so too does impurity profiling. Emerging technologies such as high-resolution mass spectrometry and automated data analysis potential to revolutionize impurity detection and characterization. Furthermore, the integration of artificial intelligence and machine learning holds potential in predicting impurity formation pathways, optimizing manufacturing processes, and ensuring product quality.

Conclusion

Impurity profiling stands as a basis of pharmaceutical quality assurance, encompassing a diverse array of analytical techniques and regulatory considerations. By identifying and quantifying impurities, manufacturers can uphold safety standards, ensure product efficacy, and safeguard public health. As the pharmaceutical aspect evolves, ongoing innovation in impurity profiling will continue to drive advancements in drug development and manufacturing practices.

References

1. Gaudette F, Bedard D, Kwan C, Frouni I, Hamadjida A, Beaudry F, et al. Highly sensitive HPLC-MS/MS assay for the quantitation of ondansetron in rat plasma and rat brain tissue homogenate following administration of a very low subcutaneous dose. J Pharm Biomed Anal. 2019;175: 112766.

   [Crossref][Google Scholar][Pubmed]

2. Kristiana E, Saefumillah A, Budianto E. Degradation of ondansetron: Isolation and characterization impurity D ondansetron as A candidate reference standard impurity in drug. AIP Conf. Proc. 2020;2242(1).

   [Crossref] [Google Scholar]

3. Liu Y, Romijn EP, Verniest G, Laukens K, De Vijlder T. Mass spectrometry-based structure elucidation of small molecule impurities and degradation products in pharmaceutical development. Trends Anal. Chem. 2019;121: 115686.

   [Crossref] [Google Scholar]

4. Görög S. Critical review of reports on impurity and degradation product profiling in the last decade. Trends Anal. Chem. 2018;101 :2-16.

   [Crossref] [Google Scholar]

5. Morsy MI, Nouman EG, Abdallah YM, Zainelabdeen MA, Darwish MM, Hassan AY. A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers. J Pharm Biomed Anal.199, p.114057.

   [Crossref][Google Scholar][Pubmed]

6. Shah VP. Progressive applications of dissolution, its impact, and implications in the pharmaceutical world. J Pharm Sci.2013;102(9):2895-2897.

   [Crossref] [Google Scholar] [Pubmed]

7. Panikar V, Chandalia HB, Joshi SR, Fafadia A, Santvana C. Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy. J Assoc Physicians India. 2003;51: 1061-1064.

   [Google Scholar] [Pubmed]

8. Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge. The lancet Diabetes & endocrinology. Lancet Diabetes Endocrinol.2014;2(1):56-64.

   [Crossref] [Google Scholar] [Pubmed]

9. Bergenstal RM, Bailey CJ, Kendall DM. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med. 2010;123(4):374-e9.

   [Crossref] [Google Scholar] [Pubmed]